Participants demographic data. by Gabriela Garcia (119921)

“…A decrease in mean erector spinae activity was observed in males only. …”

The proportion of infected sandlies. by Cameron Davis (19803404)

The risk of contracting VL. by Cameron Davis (19803404)

Experimental paradigm and BCI adaptation. by Enrico Ferrea (22331938)

SERCA is required for Ca²+ transients at E5.5. by Matthew J. Stower (22379321)

Detailed evaluation of the automated cell counting method. by Nafiseh Atapour (19727499)

<i>Copia</i> and <i>dArc1</i> have an inverse relationship at the <i>Drosophila</i> NMJ. by P. Githure M’Angale (20746093)

“…(F–I) Quantification of the data represented in A–E. Quantification of <i>dArc1</i> mRNA in the larval CNS (J), and BWM (K) of strains used in this study, showing a significant decrease of <i>copia</i> mRNA in lines with both the Gal4 driver and <i>copia</i> si/shRNA. …”

Sensitivity of temperature anomaly at 10% change in parameter values. by Athira Satheesh Kumar (20570553)

Data Sheet 1_Meigs syndrome was misdiagnosed as a malignant ovarian tumor: a case report.pdf by Hongmei Li (51944)

“…Upon admission to our institution in April 2024, imaging confirmed a large pelvic mass, and subsequent diagnostic procedures indicated a likely fibroma. …”

Bimodality of PD distributions. by Max Grogan (20384350)

Connectivity changes that underlie the main effects of hand and task epoch. by Ali Rezaei (4238548)

Considering Measurement Time and Depth in diaPASEF Plasma Proteomics by Eva R. Smit (19867170)

“…Mass spectrometry (MS)-based plasma proteomics is a powerful approach to unraveling the biology or pathophysiology in large clinical cohorts. …”

Considering Measurement Time and Depth in diaPASEF Plasma Proteomics by Eva R. Smit (19867170)

“…Mass spectrometry (MS)-based plasma proteomics is a powerful approach to unraveling the biology or pathophysiology in large clinical cohorts. …”

Source data for Fig 5. by Peiqi Yin (6533747)

“…To provide critical evidence for the potential of 4′-FlU as a CHIKV antiviral, here we selected for CHIKV variants with decreased 4′-FlU sensitivity, identifying two pairs of mutations in nsP2 and nsP4. …”

Source data for Fig 1. by Peiqi Yin (6533747)

“…To provide critical evidence for the potential of 4′-FlU as a CHIKV antiviral, here we selected for CHIKV variants with decreased 4′-FlU sensitivity, identifying two pairs of mutations in nsP2 and nsP4. …”

Source data for S6 Fig. by Peiqi Yin (6533747)

“…To provide critical evidence for the potential of 4′-FlU as a CHIKV antiviral, here we selected for CHIKV variants with decreased 4′-FlU sensitivity, identifying two pairs of mutations in nsP2 and nsP4. …”

Source data for Fig 3. by Peiqi Yin (6533747)

“…To provide critical evidence for the potential of 4′-FlU as a CHIKV antiviral, here we selected for CHIKV variants with decreased 4′-FlU sensitivity, identifying two pairs of mutations in nsP2 and nsP4. …”

Source data for Fig 4. by Peiqi Yin (6533747)

“…To provide critical evidence for the potential of 4′-FlU as a CHIKV antiviral, here we selected for CHIKV variants with decreased 4′-FlU sensitivity, identifying two pairs of mutations in nsP2 and nsP4. …”

Source data for Fig 2. by Peiqi Yin (6533747)

“…To provide critical evidence for the potential of 4′-FlU as a CHIKV antiviral, here we selected for CHIKV variants with decreased 4′-FlU sensitivity, identifying two pairs of mutations in nsP2 and nsP4. …”

Source data for Fig 6. by Peiqi Yin (6533747)

“…To provide critical evidence for the potential of 4′-FlU as a CHIKV antiviral, here we selected for CHIKV variants with decreased 4′-FlU sensitivity, identifying two pairs of mutations in nsP2 and nsP4. …”